Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Assessing the Global Burden of Post-COVID-19 Conditions
Modeling the incidence of post-COVID conditions worldwide based on real-word evidence (RWE) and clinical literature review
Dec 06, 2021
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Summary

As the number of reported cases of COVID-19 exceeds 250 million globally and deaths exceed 5 million, there is growing awareness and concern about those who suffer long-term conditions which appear to be associated with the virus. These long-term conditions are likely to impose a large burden on the healthcare system and require careful examination and understanding. However, the breadth of these conditions and their incidence remains unclear.

The objective of the research reflected in this report is to quantify the magnitude of patients with post-COVID-19 conditions based on analysis of medical open claims data and a review of the growing body of literature globally. The research also models the potential demand for medicines required to treat these patients with the post-COVID conditions, even as optimal treatment for these patients is currently based on existing therapeutics.

Key Findings

  • While there are multiple definitions of post-COVID conditions, it generally refers to an umbrella term for the wide range of physical and mental health consequences that are present after at least four weeks of infection with SARS-CoV-2.
  • Despite a growing volume of research, post-COVID conditions remain insufficiently studied, with a lack of consensus on the definition, epidemiology, underlying causes, and effective therapeutics and treatment strategies for patients.
  • Based on IQVIA U.S. medical open claims data as of June 2021, at least 22% (2.2 million) of the 9.7 million COVID-19 tagged patients in the database had one or more conditions (newly diagnosed or persistent) even after 90 days since their COVID-19 diagnosis.
  • The organ systems most frequently affected by these post-COVID conditions as per the claims data include central nervous, cardiovascular, and respiratory systems.
  • Using a global modelling approach and considering the total population diagnosed with COVID-19, at least 104.6 million newly diagnosed conditions were estimated among the reported COVID-19 survivors as of September 15, 2021. If undiagnosed cases are considered, this number would rise to at least 167.3-334.6 million conditions, assuming a factor of 3.2 undiagnosed cases for every 1 reported case in the U.S. and 50% of this factor as a conservative estimate.

Other Findings

  • Various healthcare bodies have been working to define post-COVID conditions; however, these definitions still lack clarity on the exact conditions which can be considered a part of the post-COVID.
  • Post-COVID conditions are known to affect several organ systems in the body including the central nervous system (CNS), cardiovascular system, respiratory, gastrointestinal, renal, and other systems.
  • The public impact of post-COVID conditions is being increasingly recognized by the public health bodies around the world as these groups undertake several initiatives to advance the research and understanding of post-COVID conditions.
  • While terms such as post-acute COVID syndrome, chronic COVID, long-haul COVID, late sequelae, etc., are also being used, the term ‘post-acute sequalae of SARS-CoV-2 infection (post-COVID)’ is used most commonly for research purposes.
  • Post-COVID conditions are now understood as a multi-organ disorder or syndrome that consist of a constellation of different conditions that are acute, chronic or both, and vary in terms of severity.
  • Emerging evidence highlights the post-COVID conditions as dynamic and evolving, with the latest studies reporting more than 200 conditions, which is an increase from the ~100 conditions that were being reported previously.
  • Although less severe, post-COVID conditions are also being detected in children.
  • Within CNS, anxiety disorder, fatigue and depression were the top conditions. Other organ systems including musculoskeletal, gastrointestinal, renal, endocrine, dermatology, ENT, and pediatric together contributed for the remaining 32.4% to this pool.
  • Potential direct effects on the kidney include endothelial damage from viral entry, complement activation, local inflammation, and collapsing glomerulopathy.
  • Although it is well known that acute kidney failure can lead to chronic kidney disease (CKD), knowledge of the long-term effects of COVID-19 on the kidney remains limited.
  • Based on the model calculations, at least 104.6 million conditions were estimated among the 44.2 million post-COVID patients (i.e., 20% of the report COVID-19 survivors), with an average of 2.4 conditions per patient.
  • In order to account for the undiagnosed COVID-19 cases, CDC estimates that for every single COVID-19 reported infection, more than three COVID-19 infections are not reported were assumed for all the countries. These additional number of so-called “shadow post-COVID” patients could bring the total number of post-COVID conditions to 167.3 million-334.6 million, assuming 50% and total shadow post-COVID patients.
  • Within the estimation of 104.6 million newly diagnosed conditions, the majority was represented by CNS organ system totaling nearly 28.7 million, followed by respiratory organ system totaling nearly 22.5 million, and 18.4 million newly diagnosed CVS conditions.
Contact Us